WHAT IS CLAIMED IS:

1. A method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.

2. A method of improving glycemic control in a subject having prediabetes or type 1 or type 2 diabetes comprising administering to the subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.

3. The method of claim 2, wherein said administering of imeglimin is used as an adjunct to diet and exercise.

4. The method of any one of claims 1 to 3, wherein the subject has type 2 diabetes mellitus.

5. The method of any one of claims 1 to 4, wherein the subject has moderate renal impairment or stage 3 chronic kidney disease.

6. The method of claim 5, wherein the subject has mild to moderate renal impairment or stage 3A chronic kidney disease.

7. The method of claim 5, wherein the subject has moderate to severe renal impairment or stage 3B chronic kidney disease.

8. The method of any one of claims 1 to 4, wherein the subject has severe renal impairment or stage 4 chronic kidney disease.

9. The method of any one of claims 1 to 4, wherein the subject has stage 3B or stage 4 chronic kidney disease.

10. The method of any one of claims 1 to 9, wherein the subject has an estimated glomerular filtration rate (eGFR) of between about 30 ml/min/1.73m^2 and about 59 ml/min/1.73m^2.

11. The method of claim 10, wherein the subject has an eGFR of between about 45ml/min/1.73m^2 and about 59 ml/min/1.73m^2.

12. The method of claim 10, wherein the subject has an eGFR of between about 30 ml/min/1.73m^2 and about 44 ml/min/1.73m^2.

13. The method of any one of claims 1 to 9, wherein the subject has an estimated glomerular filtration rate (eGFR) of between about 15 ml/min/1.73m^2 and about 29 ml/min/1.73m^2.

14. The method of any one of claims 1 to 9, wherein the subject has an estimated glomerular filtration rate (eGFR) of between about 15 ml/min/1.73m^2 and about 44 ml/min/1.73m^2.

15. The method of any one of claims 1 to 14, wherein the subject has a baseline glycosylated hemoglobin (HbA1c) percentage of between about 6.8% and about 12.0%.

16. The method of any one of claims 1 to 15, wherein the subject has a pre-existing medical condition.

17. The method of claim 16, wherein the pre-existing medical condition is not chronic kidney disease.

18. The method of any one of claims 1 to 15, wherein the imeglimin-treated subject has a similar or the same frequency of treatment-emergent adverse events as a placebo-treated subject.

19. The method of claim 16 or 17, wherein the imeglimin-treated subject does not experience an increase in one or more symptoms of the subject's one or more pre-existing medical conditions compared to before the subject initiated imeglimin treatment.

20. The method of claim 16 or 17, wherein the imeglimin-treated subject's one or more pre-existing conditions do not worsen in severity or symptomatology following treatment with imeglimin.

21. The method of claim 20, wherein the imeglimin-treated subject's one or more pre-existing conditions do not worsen in severity or symptomatology following treatment with imeglimin compared to before the subject initiated imeglimin treatment.

22. The method of claim 20, wherein the imeglimin-treated subject's one or more pre-existing conditions do not worsen in severity or symptomatology following treatment with imeglimin compared to that which would be expected if the subject took a second pharmaceutical agent.

23. The method of any one of claims 16 to 22, wherein the pre-existing medical condition is selected from hyperkalaemia, hypertension, cardiac disorders, gastrointestinal disorders, nervous system disorders, blood and lymphatic system disorders (such as anemia), eye disorders, endocrine disorders, or combinations thereof.

24. The method of claim 23, wherein the pre-existing medical condition is a gastrointestinal disorder.

25. The method of claim 24, wherein the gastrointestinal disorder is selected from abdominal pain, constipation, diarrhea, flatulence, gastroesophageal reflux, indigestion, nausea/vomiting, or combinations thereof.

26. The method of any one of claims 1 to 25, wherein treatment with imeglimin is well tolerated.

27. The method of any one of claims 1 to 26, wherein the imeglimin-treated subject does not experience an increase in frequency of lactic acidosis compared to before the subject initiated imeglimin treatment.

28. The method of any one of claims 1 to 27, wherein the imeglimin-treated subject does not experience an increase or elevation in plasma lactate compared to before the subject initiated imeglimin treatment.

29. The method of claim 28, wherein the imeglimin-treated subject does not experience an increase or elevation in plasma lactate above a threshold of 3 mmol/L (27 mg/dL) compared to before the subject initiated imeglimin treatment.

30. The method any one of claims 1 to 29, wherein the imeglimin-treated subject is no more likely or is less likely than a placebo-treated subject or subject treated with a second pharmaceutical agent to experience an increase or elevation in plasma lactate compared to before the subject initiated imeglimin treatment.

31. The method of any one of claims 1 to 30, wherein the subject is a human.

32. The method of any one of claims 1 to 31, wherein imeglimin is administered orally.

33. The method of any one of claims 1 to 32, wherein the amount of imeglimin administered to the subject per day is about 20% to about 100% of the amount administered to a subject with prediabetes or type 1 or type 2 diabetes mellitus but with normal kidney function.

34. The method of any one of claims 1 to 33, wherein the amount of imeglimin is about 500 mg to about 3000 mg per day.

35. The method of claim 34, wherein the amount of imeglimin is about 1000 mg to about 3000 mg per day.

36. The method of claim 35, wherein the amount of imeglimin is about 1000 mg to about 2000 mg per day.

37. The method of any one of claims 1 to 36, wherein the amount of imeglimin is about 1000 mg, about 1500 mg, or about 2000 mg per day.

38. The method of any one of claims 1 to 37, wherein imeglimin is administered once, twice, or three times per day.

39. The method of claim 38, wherein imeglimin is administered twice per day.

40. The method of claim 38, wherein imeglimin is administered 500 mg twice a day, 1000 mg twice a day, or 1500 mg once a day.

41. The method of any one of claims 1 to 40, wherein imeglimin is administered with a meal.

42. The method of any one of claims 1 to 40, wherein imeglimin is administered without a meal.

43. The method of any one of claims 1 to 42, wherein imeglimin is administered in the form of a free base or a pharmaceutically acceptable salt thereof.

44. The method of claim 43, wherein imeglimin is administered in the form a hydrochloride salt.

45. The method of any one of claims 1 to 44, wherein the subject experiences a placebo-subtracted decrease in glycosylated hemoglobin (HbA1c) percentage of between about -0.5% and about -1.2% over a treatment period.

46. The method of claim 45, wherein the subject experiences a placebo-subtracted decrease in glycosylated hemoglobin (HbA1c) percentage of between about -0.8% and about -1.1% over a treatment period.

47. The method of any one of claims 1 to 46, wherein the subject experiences a placebo-subtracted decrease in fasting plasma glucose (FPG) of between about -20 mg/dL and about -30 mg/dL over a treatment period.

48. The method of claim 47, wherein the subject experiences a placebo-subtracted decrease in fasting plasma glucose (FPG) of about -25 mg/dL over a treatment period.

49. The method of any one of claims 45 to 48, wherein the treatment period is from 4 weeks to 52 weeks.

50. The method of claim 49, wherein the treatment period is 24 weeks.

51. The method of any one of claims 1 to 50, wherein the subject has daily steady-state exposures of imeglimin ($AUC_{24,ss}$) from about 20 μg·hr/mL to about 100 μg·hr/mL.

52. The method of any one of claims 1 to 51, wherein the subject has received prior anti-diabetic treatment.

53. The method of claim 52, wherein the prior anti-diabetic treatment does not provide adequate control of or does not adequately control the subject's prediabetes or type 1 or type 2 diabetes mellitus.

54. The method of any one of claims 1 to 51, wherein the subject has not received prior anti-diabetic treatment.

55. The method of any one of claims 1 to 54, wherein imeglimin is administered with a second pharmaceutical agent.

56. The method of claim 55, wherein imeglimin is administered concomitantly with the second pharmaceutical agent.

57. The method of claim 55, wherein imeglimin is administered sequentially with the second pharmaceutical agent.

58. The method of any one of claims 55 to 57, wherein the second pharmaceutical agent is selected from the group consisting of an insulin, an alpha-glucosidase inhibitor, a biguanide, a dopamine agonist, a DPP-4 inhibitor, a glucagon-like peptide, a meglitinide, a sodium glucose transporter (SGLT2 or SGLT1/2) inhibitor, a sulfonylurea, and a thiazolidinedione.

59. The method of any one of claims 55 to 58, wherein the second pharmaceutical agent is metformin.

60. The method of any one of claims 55 to 58, wherein the second pharmaceutical agent is sitagliptin.

61. Imeglimin for use in a method for treatment of prediabetes or type 1 or type 2 diabetes mellitus of a subject, wherein the subject has chronic kidney disease.

62. Imeglimin for use in a method for improvement of glycemic control in a subject having prediabetes or type 1 or type 2 diabetes, wherein the subject has chronic kidney disease.

63. Use of imeglimin for the manufacture of a medicament for treating a subject of prediabetes or type 1 or type 2 diabetes mellitus, wherein the subject has chronic kidney disease.

64. Use of imeglimin for the manufacture of a medicament for improving glycemic control in a subject having prediabetes or type 1 or type 2 diabetes, wherein the subject has chronic kidney disease.

65. A medicament for treating prediabetes or type 1 or type 2 diabetes mellitus of a subject comprising an effective amount of imeglimin, wherein the subject has chronic kidney disease.

66. A medicament for improving glycemic control in a subject having prediabetes or type 1 or type 2 diabetes comprising an effective amount of imeglimin, wherein the subject has chronic kidney disease.

67. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein imeglimin is used as an adjunct to diet and exercise.

68. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein the subject has type 2 diabetes mellitus.

69. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein the subject has moderate renal impairment or stage 3 chronic kidney disease.

70. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein the subject has mild to moderate renal impairment or stage 3A chronic kidney disease.

71. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein the subject has moderate to severe renal impairment or stage 3B chronic kidney disease.

72. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein the subject has severe renal impairment or stage 4 chronic kidney disease.

73. The use of any one of claims 61 to 64 or the medicament of claim 65 or 66, wherein the subject has stage 3B or stage 4 chronic kidney disease.